脂蛋白(a)升高与房颤风险:观察性与孟德尔随机化研究
该研究在UK Biobank(N=435,579)中分析实测与基因预测Lp(a)水平与20,432例新发房颤的关联,并用公开GWAS汇总数据(N=1,145,375)进行孟德尔随机化。结果显示Lp(a)每升高50 nmol/L,房颤风险增加约3%,且仅39%风险通过ASCVD介导,提示Lp(a)部分独立因果影响房颤。
要点
- Lp(a)每升高50 nmol/L,新发房颤风险增加约3%,观察性与遗传学证据一致。
- LDL-C或甘油三酯未见 conferring risk 效应,Lp(a)对房颤的作用部分独立于ASCVD。
- 仅39%的Lp(a)相关房颤风险通过ASCVD介导,提示Lp(a)直接影响心肌组织。
核心结论
- Lp(a)可能是房颤发生的潜在因果介质,其效应部分独立于ASCVD。
研究设计与样本
- 在UK Biobank(N=435,579)中分析实测与基因预测Lp(a)水平与20,432例新发房颤的关联。
- 利用公开GWAS汇总数据(N=1,145,375)进行孟德尔随机化分析。
主要发现
- 实测Lp(a)每升高50 nmol/L(23 mg/dL),新发房颤风险HR为1.03(95%CI 1.02-1.04,P=1.65×10^-8)。
- 基因预测Lp(a)每升高50 nmol/L,新发房颤风险OR为1.03(95%CI 1.02-1.05,P=1.33×10^-5)。
- 独立数据孟德尔随机化重复出效应:每升高50 nmol/L,OR为1.04(95%CI 1.03-1.05,P=9.23×10^-10)。
- LDL-C或甘油三酯未见风险效应,仅39%(95%CI 27%-73%)的Lp(a)风险通过ASCVD介导。
临床怎么用
- 对房颤风险评估可关注Lp(a)水平,尤其合并ASCVD风险因素者。
- Lp(a)降低治疗的临床试验应评估对房颤预防的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Atrial fibrillation (AF) is a cardiac arrhythmia associated with an elevated risk of stroke, heart failure, and mortality. However, preventative therapies are needed with ancillary benefits on its cardiovascular comorbidities. Lipoprotein(a) (Lp[a]) is a recognized risk factor for atherosclerotic cardiovascular disease (ASCVD), which itself increases AF risk, but it remains unknown whether Lp(a) is a causal mediator of AF independent of ASCVD. OBJECTIVES: This study investigated the role of Lp(a) in AF and whether it is independent of ASCVD. METHODS: Measured and genetically predicted Lp(a) levels were tested for association with 20,432 cases of incident AF in the UK Biobank (N = 435,579). Mendelian randomization analyses were performed by using summary-level data for AF from publicly available genome-wide association studies (N = 1,145,375). RESULTS: In the UK Biobank, each 50 nmol/L (23 mg/dL) increase in Lp(a) was associated with an increased risk of incident AF using measured Lp(a) (HR: 1.03; 95% CI: 1.02-1.04 ; P = 1.65 × 10-8) and genetically predicted Lp(a) (OR: 1.03; 95% CI: 1.02-1.05; P = 1.33 × 10-5). Mendelian randomization analyses using independent data replicated the effect (OR: 1.04 per 50 nmol/L Lp[a] increase; 95% CI: 1.03-1.05 per 50 nmol/L Lp[a] increase; P = 9.23 × 10-10). There was no evidence of risk-conferring effect from low-density lipoprotein cholesterol or triglycerides, and only 39% (95% CI: 27%-73%) of Lp(a) risk was mediated through ASCVD, suggesting that Lp(a) partly influences AF independent of its known effects on ASCVD. CONCLUSIONS: Our findings implicate Lp(a) as a potential causal mediator in the development of AF which show that the effects of Lp(a) extend across myocardial tissues. Ongoing clinical trials for Lp(a)-lowering therapies should evaluate effects on AF prevention.
引用
- Mohammadi-Shemirani, Chong, Narula, et al. Elevated Lipoprotein(a) and Risk of Atrial Fibrillation: An Observational and Mendelian Randomization Study. J Am Coll Cardiol. 2022. PMID: 35450575. doi:10.1016/j.jacc.2022.02.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。